Gateway Investment Advisers LLC lowered its stake in Humana Inc. (NYSE:HUM) by 1.7% during the second quarter, according to its most recent filing with the SEC. The firm owned 9,051 shares of the insurance provider’s stock after selling 161 shares during the period. Gateway Investment Advisers LLC’s holdings in Humana were worth $2,178,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of HUM. Bank of Montreal Can boosted its position in Humana by 132.7% in the second quarter. Bank of Montreal Can now owns 379,696 shares of the insurance provider’s stock valued at $91,361,000 after buying an additional 216,528 shares during the last quarter. Atria Investments LLC boosted its position in Humana by 33.0% in the second quarter. Atria Investments LLC now owns 4,781 shares of the insurance provider’s stock valued at $1,150,000 after buying an additional 1,187 shares during the last quarter. Capstone Asset Management Co. boosted its position in Humana by 5.8% in the second quarter. Capstone Asset Management Co. now owns 17,773 shares of the insurance provider’s stock valued at $4,277,000 after buying an additional 968 shares during the last quarter. Xact Kapitalforvaltning AB boosted its position in Humana by 2.0% in the second quarter. Xact Kapitalforvaltning AB now owns 23,365 shares of the insurance provider’s stock valued at $5,622,000 after buying an additional 455 shares during the last quarter. Finally, Independent Portfolio Consultants Inc. boosted its position in Humana by 22.1% in the second quarter. Independent Portfolio Consultants Inc. now owns 519 shares of the insurance provider’s stock valued at $125,000 after buying an additional 94 shares during the last quarter. Hedge funds and other institutional investors own 99.62% of the company’s stock.
Shares of Humana Inc. (NYSE HUM) traded down 1.17% during mid-day trading on Friday, hitting $245.93. The stock had a trading volume of 1,557,990 shares. Humana Inc. has a 12 month low of $163.50 and a 12 month high of $251.79. The stock has a market cap of $35.54 billion, a P/E ratio of 20.23 and a beta of 0.91. The firm has a 50 day moving average price of $236.19 and a 200-day moving average price of $220.68.
Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, August 2nd. The insurance provider reported $3.49 EPS for the quarter, beating the consensus estimate of $3.08 by $0.41. The firm had revenue of $13.53 billion for the quarter, compared to analyst estimates of $13.61 billion. Humana had a return on equity of 15.85% and a net margin of 3.37%. During the same period in the prior year, the company earned $2.30 EPS. On average, equities research analysts forecast that Humana Inc. will post $11.40 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This article was reported by BNB Daily and is owned by of BNB Daily. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://www.baseball-news-blog.com/2017/08/06/gateway-investment-advisers-llc-has-2-18-million-position-in-humana-inc-hum-updated-updated.html.
Several research analysts have weighed in on the company. Jefferies Group LLC reiterated a “hold” rating and set a $257.00 price objective on shares of Humana in a research report on Friday. Cantor Fitzgerald restated a “neutral” rating and issued a $223.00 price target (up previously from $200.00) on shares of Humana in a research report on Thursday. Oppenheimer Holdings, Inc. raised their price target on Humana from $236.00 to $255.00 and gave the stock an “outperform” rating in a research report on Thursday. Credit Suisse Group restated an “outperform” rating and issued a $260.00 price target (up previously from $250.00) on shares of Humana in a research report on Thursday. Finally, Piper Jaffray Companies raised their price target on Humana to $280.00 and gave the stock an “overweight” rating in a research report on Thursday. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $241.65.
In related news, SVP Brian P. Leclaire sold 4,971 shares of the stock in a transaction dated Wednesday, June 28th. The stock was sold at an average price of $240.00, for a total transaction of $1,193,040.00. Following the completion of the sale, the senior vice president now directly owns 14,258 shares in the company, valued at approximately $3,421,920. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Heidi S. Margulis sold 1,500 shares of the stock in a transaction dated Friday, May 26th. The shares were sold at an average price of $231.96, for a total value of $347,940.00. Following the sale, the vice president now owns 8,150 shares of the company’s stock, valued at $1,890,474. The disclosure for this sale can be found here. 0.80% of the stock is currently owned by corporate insiders.
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Humana Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.